These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 10161873)
1. Cancer coverage. Why are insurers paying for this "experimental" therapy? Med Econ; 1996 Sep; 73(17):38. PubMed ID: 10161873 [No Abstract] [Full Text] [Related]
2. Current legal intervention regarding "experimental" treatments must be changed: an analysis of high doses of chemotherapy with autologous bone marrow transplantation for breast cancer patients. Smayda E J Law Health; 1998-1999; 13(2):257-80. PubMed ID: 10947396 [No Abstract] [Full Text] [Related]
3. Experimental medical treatments: who should decide coverage? Collins JC Spec Law Dig Health Care Law; 1998 Jan; (226):9-45. PubMed ID: 10176412 [No Abstract] [Full Text] [Related]
4. Health insurance: coverage of autologous bone marrow transplantation for breast cancer. Jaggar SF Oncology (Williston Park); 1996 Sep; 10(9):1329-32, 1337-8, 1340 passim. PubMed ID: 8882925 [No Abstract] [Full Text] [Related]
5. ABMT and breast cancer. Firshein J Healthplan; 1999; 40(4):30-3, 35-7. PubMed ID: 10557735 [No Abstract] [Full Text] [Related]
6. Experimental medical treatments: who should decide coverage? Collins JC Seattle Univ Law Rev; 1997; 20(2):451-87. PubMed ID: 16528856 [No Abstract] [Full Text] [Related]
7. Litigating the science of breast cancer treatment. Jacobson PD; Rettig RA; Aubry WM J Health Polit Policy Law; 2007 Oct; 32(5):785-818. PubMed ID: 17855717 [TBL] [Abstract][Full Text] [Related]
8. Health insurance coverage for emerging medical technologies: a new approach. Puzio D Tort Trial Insur Pract Law J; 2003; 38(4):1019-47. PubMed ID: 14503539 [No Abstract] [Full Text] [Related]
9. Last chance therapies and managed care. Pluralism, fair procedures, and legitimacy. Daniels N; Sabin JE Hastings Cent Rep; 1998; 28(2):27-41. PubMed ID: 9589291 [TBL] [Abstract][Full Text] [Related]
10. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. Peters WP; Rogers MC N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855 [TBL] [Abstract][Full Text] [Related]
11. Perspectives. Indefinite results in ABMT (autologous bone marrow transplantation) trials add to challenges for practice standards, quality assurance in cancer care. Cunningham R Med Health; 1999 Apr; 53(16):suppl 1-4. PubMed ID: 10387749 [No Abstract] [Full Text] [Related]
12. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer. Cutler CM; Udvarhelyi IS; Winkenwerder W N Engl J Med; 1994 Aug; 331(5):329-30. PubMed ID: 8022449 [No Abstract] [Full Text] [Related]
13. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer. Krause KJ N Engl J Med; 1994 Aug; 331(5):329; author reply 330-1. PubMed ID: 8068113 [No Abstract] [Full Text] [Related]
14. New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer. Lucey C; Westphal JR South Med J; 1998 Feb; 91(2):196-201. PubMed ID: 9496875 [TBL] [Abstract][Full Text] [Related]
15. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer. Wingard JR N Engl J Med; 1994 Aug; 331(5):330; author reply 330-1. PubMed ID: 8022452 [No Abstract] [Full Text] [Related]
16. Autologous bone marrow transplantation for advanced breast cancer. Med Lett Drugs Ther; 1991 May; 33(843):39-40. PubMed ID: 2014014 [No Abstract] [Full Text] [Related]
17. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Mello MM; Brennan TA Health Aff (Millwood); 2001; 20(5):101-17. PubMed ID: 11558695 [TBL] [Abstract][Full Text] [Related]